2017
Hospital-Readmission Risk — Isolating Hospital Effects from Patient Effects
Krumholz HM, Wang K, Lin Z, Dharmarajan K, Horwitz LI, Ross JS, Drye EE, Bernheim SM, Normand ST. Hospital-Readmission Risk — Isolating Hospital Effects from Patient Effects. New England Journal Of Medicine 2017, 377: 1055-1064. PMID: 28902587, PMCID: PMC5671772, DOI: 10.1056/nejmsa1702321.Peer-Reviewed Original ResearchConceptsRisk-standardized readmission ratesReadmission ratesObserved readmission ratesSimilar diagnosesHospital effectsDifferent hospitalsHospital readmission performanceRate of readmissionHospital readmission ratesLower readmission ratesStudy sampleYears of ageSignificant differencesMultiple admissionsReadmission outcomesOnly significant differencePatient effectsSame patientMedicare recipientsPatientsReadmission performanceRisk-standardized hospital readmission ratesHospitalHospital qualityQuartile
2013
The cost implications of prostate cancer screening in the Medicare population
Ma X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.Peer-Reviewed Original ResearchConceptsProstate cancerScreening costsAnnual screening costsPopulation-based cohortProstate cancer screeningHospital referral region levelMale Medicare beneficiariesProstate-specific antigenCancer screeningLowest quartileHRR levelMedicare populationMedicare beneficiariesOlder menNational feeCancerService Medicare programCancer diagnosisMenQuartilePSACost implicationsAnnual expenditureMedicare programBiopsy